Immunic, Inc. financial data

Symbol
IMUX on Nasdaq
Industry
Pharmaceutical Preparations
Location
1200 Avenue Of The Americas, Suite 200, New York, United States
State of incorporation
DE
Fiscal year end
December 31
Former names
VITAL THERAPIES INC (to 4/10/2019)
Latest financial report
10-K - Q4 2024 - Mar 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 328 % -18.6%
Debt-to-equity 43.3 % +27%
Return On Equity -194 % -23.5%
Return On Assets -136 % -15.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 90.2M shares +0.08%
Common Stock, Shares, Outstanding 90.2M shares +99.5%
Entity Public Float 100M USD -8.68%
Common Stock, Value, Issued 8K USD +100%
Weighted Average Number of Shares Outstanding, Basic 100M shares +126%
Weighted Average Number of Shares Outstanding, Diluted 100M shares +126%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 80M USD -3.81%
General and Administrative Expense 18M USD +12.5%
Operating Income (Loss) -98.1M USD +1.18%
Nonoperating Income (Expense) -2.46M USD -144%
Net Income (Loss) Attributable to Parent -101M USD -7.37%
Earnings Per Share, Basic -1 USD/shares +52.6%
Earnings Per Share, Diluted -1 USD/shares +52.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 35.7M USD -23.6%
Other Assets, Current 1.11M USD +3.74%
Assets, Current 39.3M USD -25.1%
Property, Plant and Equipment, Net 545K USD +17%
Operating Lease, Right-of-Use Asset 991K USD -23.7%
Other Assets, Noncurrent 0 USD -100%
Assets 40.9M USD -24.7%
Accounts Payable, Current 7.85M USD +53.9%
Accrued Liabilities, Current 12.9M USD -30.8%
Liabilities, Current 22.2M USD -10.3%
Operating Lease, Liability, Noncurrent 264K USD -58.7%
Liabilities 22.4M USD -11.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 4.21M USD +12%
Retained Earnings (Accumulated Deficit) -511M USD -24.5%
Stockholders' Equity Attributable to Parent 18.4M USD -36.3%
Liabilities and Equity 40.9M USD -24.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -24M USD -22.8%
Net Cash Provided by (Used in) Financing Activities 74.5M USD +145908%
Net Cash Provided by (Used in) Investing Activities -31K USD -101%
Common Stock, Shares Authorized 500M shares +285%
Common Stock, Shares, Issued 90.2M shares +99.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 50.6M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 35.7M USD -23.6%
Deferred Tax Assets, Valuation Allowance 117M USD +18.2%
Deferred Tax Assets, Gross 117M USD +18.2%
Operating Lease, Liability 1M USD -24.7%
Depreciation 42K USD +23.5%
Payments to Acquire Property, Plant, and Equipment 31K USD -70.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -100M USD -7.72%
Lessee, Operating Lease, Liability, to be Paid 1.06M USD -26.8%
Operating Lease, Liability, Current 740K USD +6.48%
Lessee, Operating Lease, Liability, to be Paid, Year Two 167K USD -63%
Lessee, Operating Lease, Liability, to be Paid, Year One 740K USD -2.38%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 56K USD -50.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 78K USD 0%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 75K USD -8.54%
Additional Paid in Capital 526M USD +20.5%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 26K USD -18.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%